摘要
目的 观察补肺活血胶囊治疗缓解期慢性肺源性心脏病的临床疗效及对免疫球蛋白的影响。方法 将2019年6月至2021年6月于我院就诊的64例缓解期慢性肺源性心脏病患者作为研究对象,根据治疗方法不同分为观察组和对照组,所有患者接受慢性肺源性心脏病标准化治疗,观察组加用补肺活血胶囊治疗。比较2组患者治疗前后中医证候疗效评定;比较2组患者干预前后自我评估测试评分(CAT评分)。运用Borg评分评价患者的肺康复效果,通过检测血中免疫球蛋白(Ig)A、IgG、IgM水平,比较2组患者的免疫球蛋白水平。结果 治疗后观察组中医证候评分为(6.8±1.0)分,低于对照组(8.4±1.0),差异具有统计学意义(P<0.05);观察组总有效率为81%,高于对照组的53%,差异具有统计学意义(P<0.05)。干预前观察组CAT评分、Borg评分与对照组比较,差异无统计学意义(P>0.05),干预后CAT评分、Borg评分优于对照组(P<0.05)。干预前观察组IgA、IgG、IgM水平与对照组比较,差异无统计学意义(P>0.05),干预后2组患者IgA、IgG、IgM水平升高,观察组高于对照组,差异有统计学意义(P<0.05)。观察组口干、便秘、肠梗阻的发生例数分别为1例、3例、0例,不良反应发生率为13%,对照组口干、便秘、肠梗阻的发生例数分别为2例、3例、0例,不良反应发生率为16%,2组差异无统计学意义(P>0.05)。结论 补肺活血胶囊治疗缓解期慢性肺源性心脏病的临床疗效确切,同时可提高患者的免疫球蛋白水平,无严重不良反应发生,值得在临床推广。
Objective To investigate the clinical efficacy of Bufei Huoxue Capsules as a treatment of chronic cor pulmonale in remission and its effect on immunoglobulin levels.Methods A total of 64 patients with chronic cor pulmonale in remission treated in our hospital between June 2019 and June 2021 were included and divided into a study group and a control group by the treatment.All patients received standardized treatment for chronic cor pulmonale.In addition to this,the study group was given Bufei Huoxue Capsules.The two groups were compared for efficacy by evaluating the TCM syndrome score and patient-rated COPD assessment test(CAT) score before and after the intervention.Borg score was used to evaluate the outcome of pulmonary rehabilitation in the patients.Measurement of the serum immunoglobulin A(IgA),IgG and IgM levels was performed to compare immune function between the two groups of patients.Results After treatment,the TCM syndrome score was lower in the study group than that in the control group [(6.8 ±1.0) vs(8.4±1.0)],with statistically significant difference(P0.05);after intervention,the CAT and Borg scores were more favorable in the study group than those in the control group(P0.05);after intervention,the levels of IgA,IgG,and IgM increased in either group,and differed statistically between the two groups(P0.05).Conclusion Bufei Huoxue Capsules may lead to definite clinical efficacy as a treatment of chronic cor pulmonale in remission,improve the immune function in these patients with no serious adverse reactions,and thus is worthwhile for widespread use in clinical setting.
作者
倪红燕
杨文林
王海峰
Ni Hongyan;Yang Wenlin;Wang Haifeng(Department of Respiratory Medicine,Wusong Hospital,Zhongshan Hospital Affiliated to Fudan University,Shanghai 200940,China)
出处
《中国药物与临床》
CAS
2022年第7期622-625,共4页
Chinese Remedies & Clinics
关键词
肺心病
治疗结果
免疫球蛋白类
补肺活血胶囊
Pulmonary heart disease
Treatment outcome
Immanoglobulins
Bufei Huoxue Capsule
